Anatomic stage ii breast cancer ajcc v8 Trials in O'Fallon, United States
Conditions / Anatomic stage ii breast cancer ajcc v8 / O'Fallon, United States
Research into Anatomic stage ii breast cancer ajcc v8 spans multiple therapeutic approaches and trial phases.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05812807 | Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | RECRUITING | PHASE3 |
| NCT04266249 | CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05568472 | Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study | ACTIVE_NOT_RECRUITING | NA |
| NCT04457596 | T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06876714 | ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab | RECRUITING | PHASE3 |
| NCT03939481 | Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT05929768 | Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | RECRUITING | PHASE3 |
| NCT06058377 | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | RECRUITING | — |
| NCT04001829 | Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT04379570 | Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy | ACTIVE_NOT_RECRUITING | PHASE3 |